Global Plasma Protease C1-Inhibitor Market is valued approximately USD 3752.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.72% over the forecast period 2024-2032. Plasma Protease C1-Inhibitor, also referred to as C1-INH or C1 esterase inhibitor, is a vital protein present in the blood. It plays a key role in regulating the complement system and controlling inflammation. As a natural inhibitor of several proteases, including C1s and C1r, which are components of the classical pathway of the complement system, C1-INH helps prevent excessive activation of the complement cascade. By doing so, it inhibits the production of inflammatory mediators, maintaining immune homeostasis and preventing tissue damage. The rising shift towards early diagnosis and improved awareness is a key trend that the supporting the growth of Global Plasma Protease C1-Inhibitor Market during the estimated period of 2024-2032. Growing awareness among the public and healthcare professionals about Hereditary Angioedema (HAE) is resulting in earlier diagnoses. This has led to a larger number of patients seeking treatment, consequently driving the market demand for C1-inhibitor therapies.

The rising prevalence of HAE globally is a significant driver for the demand for Plasma Protease C1-Inhibitor products, as they are crucial for managing and treating this rare genetic disorder. Accordingly, increased public and medical professional awareness of HAE leads to earlier diagnosis and a rise in patients seeking treatment. Besides HAE, Plasma Protease C1-Inhibitor products are being explored for their potential in treating other conditions related to complement system disorders and inflammatory diseases, contributing to market expansion. Moreover, rising investment in research and development, the discovery of new inhibitor drugs, growing product approvals and the development of promising pipeline drugs and novel therapies for treating hereditary angioedema are among the key factors propelling the global market growth during the estimated period. However, high price of esoteric testing procedures and stringent regulatory requirements is expected stifle market growth between 2022 and 2032.

The key regions considered for the global Plasma Protease C1-Inhibitor Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America leads the global Plasma Protease C1-Inhibitor market in terms of revenue due to the growing prevalence of Hereditary Angioedema (HAE). Also, pharmaceutical companies in North America are actively involved in researching and developing new and improved C1-inhibitor therapies. This includes exploring alternative delivery methods, extended-release formulations and even gene therapies for HAE. The region benefits from a robust healthcare infrastructure, frequent product approvals, and major market players offering effective treatments for HAE patients. Favorable regulatory policies and approvals for Plasma Protease C1-Inhibitor products are facilitating their accessibility and adoption in North America, contributing to market expansion. The market in Asia Pacific, on the other hand, is expected to grow at the fastest rate over the forecast period.

Major market player included in this report are:
CSL Limited (CSL Behring LLC)
Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
Ionis Pharmaceuticals, Inc.
Pharming Technologies B.V.
Centogene AG
BioCryst Pharmaceuticals
KalVista Pharmaceuticals, Inc.
Fresenius Kabi
Octapharma AG
Kedrion S.p.A.
The detailed segments and sub-segment of the market are explained below:
By Drug Type
C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage Form
Lyphophlised
Injectables
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market